Literature DB >> 3567022

The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction.

D E Price, A Mehta, B K Park, A Hay, M P Feely.   

Abstract

The effects of low-dose phenobarbitone on three indices of hepatic enzyme induction were studied. Eight healthy volunteers took phenobarbitone 7.5 mg daily for 4 weeks followed by 15 mg daily for 4 weeks; five subjects took 30 mg daily for a further 2 weeks. Phenobarbitone 15 mg daily produced a significant rise in antipyrine clearance (P less than 0.05). Phenobarbitone 30 mg daily produced a further rise, but probably because of the reduced numbers of subjects, this did not achieve significance (P = 0.06). Urinary 6-beta-hydroxycortisol and D-glucaric acid levels did not change significantly and remained within the range seen in subjects not taking enzyme-inducing drugs. We conclude that phenobarbitone 7.5 mg daily produces little (if any) enzyme induction whereas 15 mg, or more, may have the potential to produce drug interactions through enzyme induction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3567022      PMCID: PMC1401201          DOI: 10.1111/j.1365-2125.1986.tb02970.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

Review 1.  Clinical implications of enzyme induction.

Authors:  A Breckenridge
Journal:  Basic Life Sci       Date:  1975

2.  Dose-dependent enzyme induction.

Authors:  A Breckenridge; M L Orme; L Davies; S S Thorgeirsson; D S Davies
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Urinary D-glucaric acid assay by an improved enzymatic procedure.

Authors:  C J Simmons; M Davis; B Dordoni; R Williams
Journal:  Clin Chim Acta       Date:  1974-02-28       Impact factor: 3.786

4.  Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects.

Authors:  E Perucca; M Ruprah; A Richens; B K Park; D J Betteridge; A M Hedges
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

5.  Phenobarbital in the monitoring of compliance.

Authors:  M Feely; D Price; J Cooke
Journal:  Ann Intern Med       Date:  1984-07       Impact factor: 25.391

6.  Analysis of barbiturates in blood by high-performance liquid chromatography.

Authors:  R Gill; A A Lopes; A C Moffat
Journal:  J Chromatogr       Date:  1981-11-13

7.  A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine.

Authors:  B K Park
Journal:  J Steroid Biochem       Date:  1978-10       Impact factor: 4.292

8.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

9.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors:  M Danhof; E de Groot-van der Vis; D D Breimer
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

10.  Effect of low-dose phenobarbital on hepatic microsomal UDP-glucuronyl transferase activity.

Authors:  N Tavoloni; R Wittman; M J Jones; P D Berk
Journal:  Biochem Pharmacol       Date:  1983-07-15       Impact factor: 5.858

View more
  10 in total

1.  A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteers.

Authors:  E Hardy; S Kumar; S Peaker; M Feely; T Pullar
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

2.  The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance.

Authors:  T Pullar; S Kumar; H Chrystyn; P Rice; S Peaker; M Feely
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

3.  Compliance with oral corticosteroids during steroid trials in chronic airways obstruction.

Authors:  M Q Hatton; M B Allen; S V Vathenen; M P Feely; N J Cooke
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

4.  Use of a pharmacological indicator to monitor compliance with thyroxine.

Authors:  N D Penn; S Peaker; A P Griffiths; M Feely; H Tindall
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

6.  Low-dose phenobarbitone as an indicator of compliance with drug therapy.

Authors:  M Feely; J Cooke; D Price; S Singleton; A Mehta; L Bradford; R Calvert
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

7.  Pharmacokinetics of phenobarbital in the cat following multiple oral administration.

Authors:  S M Cochrane; J M Parent; W D Black; D G Allen; J H Lumsden
Journal:  Can J Vet Res       Date:  1990-06       Impact factor: 1.310

Review 8.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

9.  Measuring treatment compliance of men with non-gonococcal urethritis receiving oxytetracycline combined with low dose phenobarbitone.

Authors:  C J Bignell; F M Mulcahy; S Peaker; T Pullar; M P Feely
Journal:  Genitourin Med       Date:  1988-10

Review 10.  Antenatal phenobarbital for reducing neonatal jaundice after red cell isoimmunization.

Authors:  J T Thomas; P Muller; C Wilkinson
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.